Order Article Reprints

Baldin P, Carrasco J, Beniuga G, Jouret-Mourin A, Demolin G, Roland S, D’Hondt L, Vergauwe P, Van Daele D, Mailleux M, et al. Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial). Cancers. 2022; 14(5):1183. https://doi.org/10.3390/cancers14051183

Baldin, Pamela, Javier Carrasco, Gabriela Beniuga, Anne Jouret-Mourin, Gauthier Demolin, Sandrine Roland, Lionel D’Hondt, Philippe Vergauwe, Daniel Van Daele, Marie Mailleux, and et al. 2022. "Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial)" Cancers 14, no. 5: 1183. https://doi.org/10.3390/cancers14051183

Baldin, P., Carrasco, J., Beniuga, G., Jouret-Mourin, A., Demolin, G., Roland, S., D’Hondt, L., Vergauwe, P., Van Daele, D., Mailleux, M., Sinapi, I., De Cuyper, A., Blétard, N., Massart, B., Delos, M., Castella, M.-L., van Maanen, A., & Van den Eynde, M. (2022). Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial). Cancers, 14(5), 1183. https://doi.org/10.3390/cancers14051183